Thiazolidinediones
Thiazolidinediones has been studied in 120 papers since 2007: 1 trial and 43 observational studies in people, 2 in animals, 72 reviews; 57 in the past year. The newest paper, Nov 18, 2026: “Comparative Risk of Incident Autoimmune Diseases by First Add-on Antidiabetic Drug Class After Metformin: A Population-Based Active-Comparator, New-User Cohort Study”.
15 new papers in 30 daysSee all 119 papers on thiazolidinediones
At a glance
Independent labs found the same change in people. 23 independent labs in 10 countries; 2 trials, none about aging, 1 with no results posted.
“Thiazolidinedione use (hazard ratio [HR] 1.22; 95% CI, 1.02-1.46) and insulin use (HR 1.34, 95% CI, 1.08-1.66) were significant diabetes-related predictors of all clinical fractures.”
1 of its findings points the other way.
- 23 independent labs in 10 countries
- 1 finding against
- 2 trials, none about aging, 1 with no results posted
- Funders: National Institutes of Health and others
- 4 of 25 findings with company ties
- Human trial1
- Humans43
- Model organisms2
- In silico2
What did studies of thiazolidinediones find?
9Studies of thiazolidinediones measured 9 outcomes; the most studied is inflammation (3 studies).
Inflammation
downin reviews2downin humans1
3 studies
Inflammation
downin reviews2downin humans1
Thiazolidinediones are linked with inflammation in humans (type 2 diabetes mellitus).
“SGLT-2 inhibitors and TZDs demonstrated stronger and more integrated anti-inflammatory networks, whereas Biguanidines and DPP-4 inhibitors exhibited moderate coherence.”
Humanstype 2 diabetes mellitusone yearn = 13,425
Journal of clinical medicine
Thiazolidinediones decrease inflammation.
“TZDs exert anti-inflammatory effects that may reduce obesity-related cancer risks.”
Review
Type 2 diabetes medications and their implications for cancer treatment: A comprehensive review
Molecular aspects of medicine
Thiazolidinediones decrease inflammation (preclinical models of Alzheimer's disease).
“TZDs ameliorated neuroinflammation and ferroptosis in preclinical models of AD.”
Reviewpreclinical models of Alzheimer's disease
Journal of Alzheimer's disease : JAD
Dementia
no changein humans1
1 study
Dementia
no changein humans1
Thiazolidinediones were not clearly linked with dementia in humans.
“Dementia risk was similar for TZDs, DPP-4inhibitors and SUs”
Humanscompared with dipeptidyl peptidase-4 inhibitors and sulfonylureas, in adults with type 2 diabetes on metforminup to 5 years
medRxivPreprint
Vascular dementia
no changein humans1
1 study
Vascular dementia
no changein humans1
Thiazolidinediones were not clearly linked with vascular dementia in humans (aHR 0.89 (95% CI 0.36-2.23)).
“TZD were associated with a similar risk of vascular dementia compared with DPP-4 inhibitors (aHR 0.89;95% CI 0.36-2.23)”
Humanscompared with dipeptidyl peptidase-4 inhibitors, in adults with type 2 diabetes on metforminup to 5 years
medRxivPreprint
Breast cancer-related lymphedema
no changein humans1
1 study
Breast cancer-related lymphedema
no changein humans1
Thiazolidinediones showed no clear effect on breast cancer-related lymphedema in humans (stage I-III breast cancer).
“thiazolidinediones, anti-hypertensives, and non-steroidal anti-inflammatory drugs (NSAIDs) had no effect on BCRL incidence”
Reviewstage I-III breast cancer
Frontiers in oncology
Bone mineral density
downin humans1
1 study
Bone mineral density
downin humans1
Thiazolidinediones are linked with lower bone mineral density in men with type 2 diabetes.
“Among men with type 2 diabetes, TZD, insulin, and sulfonylurea use were associated with greater hip BMD loss.”
Humansin men with type 2 diabeteshipmales
The Journal of clinical endocrinology and metabolism
mvAge
downin humans1
1 study
mvAge
downin humans1
Thiazolidinediones are linked with lower mvAge in humans (genetically proxied, drug-target Mendelian randomization) (P value = 3.50 × 10−10).
“Similarly, genetically proxied thiazolidinediones (P value = 3.50 × 10−10)”
Humansgenetically proxied, drug-target Mendelian randomization
Nature aging
Ferroptosis
downin reviews1
1 study
Ferroptosis
downin reviews1
Thiazolidinediones decrease ferroptosis (preclinical models of Alzheimer's disease).
“TZDs ameliorated neuroinflammation and ferroptosis in preclinical models of AD.”
Reviewpreclinical models of Alzheimer's disease
Journal of Alzheimer's disease : JAD
Glycemic control
upin humans1
1 study
Glycemic control
upin humans1
Thiazolidinediones improve glycemic control in humans.
“Thiazolidine derivatives and metformin are effective for glycemic control”
Review
Management guideline for Werner syndrome 2020. 3. Diabetes associated with Werner syndrome
Geriatrics & gerontology international
Egg-laying rate
upin worms1
1 study
Egg-laying rate
upin worms1
Thiazolidinediones improve egg-laying rate in worms (high glucose).
“Antidiabetic drugs of the biguanide and thiazolidine classes ameliorated the detrimental effect of glucose on egg-laying rate”
Model organismshigh glucose
Glucose-induced abnormal egg-laying rate in Caenorhabditis elegans
Bioscience, biotechnology, and biochemistry
What is thiazolidinediones linked with?
15Studies link thiazolidinediones with 15 measures, among them bone fracture, dementia and autoimmune rheumatic disease.
Bone fracture
upin humans3upin reviews1HR 1.22
4 studies
Bone fracture
upin humans3upin reviews1HR 1.22
Thiazolidinediones predict bone fracture in humans (type 2 diabetes and overweight or obesity) (HR 1.22; 95% CI, 1.02-1.46).
“Thiazolidinedione use (hazard ratio [HR] 1.22; 95% CI, 1.02-1.46) and insulin use (HR 1.34, 95% CI, 1.08-1.66) were significant diabetes-related predictors of all clinical fractures.”
Human trialtype 2 diabetes and overweight or obesity
The Journal of clinical endocrinology and metabolism
Thiazolidinediones raise the risk of bone fracture.
“thiazolidinediones, sulfonylurea and some insulin regimens increase fracture risk”
Review
Polypharmacy and Bone Health in Patients with Type 2 Diabetes Mellitus: A Narrative Review
Journal of bone metabolism
Thiazolidinediones are associated with bone fracture in humans.
“Thiazolidinediones (TZDs) were linked with increased fracture risk”
Review
Diabetology & metabolic syndrome
Thiazolidinediones raise the risk of bone fracture in patients with diabetes mellitus.
“Some studies suggest that TZDs may have negative impact on bone health by decreasing bone formation and increasing the fracture risk.”
Reviewin patients with diabetes mellitus
The effect of antidiabetic drugs on bone metabolism: a concise review
Endocrine
Dementia
downin humans4RR 0.78
4 studies
Dementia
downin humans4RR 0.78
Thiazolidinediones are linked with a lower risk of dementia in humans (network meta-analysis of observational studies, compared with non-users) (OR 0.68 (95% CI 0.57 to 0.81)).
“thiazolidinedione (TZD) (OR = 0.68, 95%CI, 0.57 to 0.81)”
Humansnetwork meta-analysis of observational studies, compared with non-users
Alzheimer's research & therapy
Thiazolidinediones are linked with a lower risk of dementia in humans (people with diabetes, pooled cohort and case-control studies).
“Metformin, thiazolidinediones, pioglitazone, GLP1RAs and SGLT2is were associated with significant reduction in risk of dementia.”
Humanspeople with diabetes, pooled cohort and case-control studiesn = 3,046,661
Diabetes, obesity & metabolism
Thiazolidinediones are linked with a lower risk of dementia in humans (compared with metformin monotherapy) (22% lower risk; HR 0.78, 95% CI 0.75 to 0.81).
“After at least 1 year of treatment, TZD monotherapy was associated with a 22% lower risk of all-cause dementia onset (HR 0.78, 95% CI 0.75 to 0.81)”
Humanscompared with metformin monotherapyat least 1 year of treatment
BMJ open diabetes research & care
Thiazolidinediones lower the risk of dementia in longitudinal studies of people with diabetes (RR 0.78 [0.76, 0.81]).
“Meta‐analysis of 7 longitudinal studies showed glitazones ( n = 1,081,519, RR=0.78[0.76,0.81], I 2 =0%) were associated with reduced dementia risk.”
Reviewin longitudinal studies of people with diabetes
AAIC 2025 abstract
Autoimmune rheumatic disease
downin humans1
1 study
Autoimmune rheumatic disease
downin humans1
Thiazolidinediones are associated with autoimmune rheumatic disease in humans (Type 2 diabetes; first add-on to metformin; compared with DPP-4 inhibitors) (aHR 0.65, 95% CI 0.42–1.01).
“1.11 (95% CI, 0.94–1.29) for sulfonylureas and 0.65 (95% CI, 0.42–1.01) for thiazolidinediones.”
HumansType 2 diabetes; first add-on to metformin; compared with DPP-4 inhibitors
Research SquarePreprint
Aortic aneurysm
downin humans1
1 study
Aortic aneurysm
downin humans1
Thiazolidinediones are associated with aortic aneurysm in humans (type 2 diabetes mellitus) (aHR 0.71, 95% CI 0.65–0.77).
“thiazolidinediones (aHR 0.71, 95% CI 0.65 - 0.77)”
Humanstype 2 diabetes mellitus8.5 ± 4.7 years52.8% mensn = 3,295,564
European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery
Pancreatic cancer
upin humans1HR 1.3
1 study
Pancreatic cancer
upin humans1HR 1.3
Thiazolidinediones are linked with a higher risk of pancreatic cancer in humans (compared with GLP-1 RA users, propensity score-matched) (HR 1.30, 95% CI 1.001–1.678; absolute risk difference 0.15 percentage points).
“thiazolidinediones (HR 1.30, 95% CI 1.001, 1.678; ARD 0.15% points)”
Humanscompared with GLP-1 RA users, propensity score-matched
Journal of gastrointestinal cancer
Mortality
downin humans1HR 0.838
1 study
Mortality
downin humans1HR 0.838
Thiazolidinediones are linked with a lower risk of mortality in humans (HR 0.838, 95% CI 0.793-0.885).
“metformin and thiazolidinedione (TZD) exposure were associated with lower mortality (HR 0.828, 95% CI 0.799-0.857 and HR 0.838, 95% CI 0.793-0.885, respectively)”
Humansafter adjustment for demographics, comorbid conditions, renal function, and hemoglobin A1c; veterans with pulmonary hypertension and diabetes
Pulmonary circulation
Chronic respiratory disease
downin humans1OR 0.79
1 study
Chronic respiratory disease
downin humans1OR 0.79
Thiazolidinediones lower the risk of chronic respiratory disease in type 2 diabetes (OR 0.79, 0.69-0.91).
“Thiazolidinediones reduced incident CRD by 21% (odds ratio (OR) 0.79, 0.69-0.91)”
Reviewin type 2 diabetesn = 939,064
Therapeutic advances in endocrinology and metabolism
Cognitive function
upin humans1
1 study
Cognitive function
upin humans1
Thiazolidinediones are associated with cognitive function in type 2 diabetes mellitus.
“GLP-1 agonists, SGLT-2 inhibitors, and glitazones have a more robust association with a possible cognitive benefit”
Reviewin type 2 diabetes mellitus
Antidiabetic agents and risk of dementia in type 2 diabetes
Asclepius International Journal of Scientific Health Science
Atrial fibrillation
upin humans1
1 study
Atrial fibrillation
upin humans1
Thiazolidinediones are linked with a higher risk of atrial fibrillation in humans (type 2 diabetes, compared with SGLT2 inhibitors) (SHR 1.22, 95% CI 1.09-1.36).
“Compared with SGLT2 inhibitors, the risk of AF was significantly higher in patients using thiazolidinediones (subdistribution hazard ratio [SHR], 1.22; 95% confidence interval [CI], 1.09-1.36)”
Humanstype 2 diabetes, compared with SGLT2 inhibitorsmean follow-up of 6.2 yearsn = 36,744
Cardiovascular diabetology
Osteoporosis
upin humans1HR 1.39
1 study
Osteoporosis
upin humans1HR 1.39
Thiazolidinediones are linked with a higher risk of osteoporosis in humans (multivariate Cox regression; compared with metformin) (HR 1.39 (1.01–1.92)).
“For Diabetes-related risk factors, dipeptidyl peptidase-4 inhibitors (DPP4-inhibitors), insulin, and thiazolidinediones were associated with a higher risk of osteoporosis; HR were 1.36 (1.05–1.75), 1.32 (1.05–1.65), and 1.39 (1.01–1.92), respectively.”
Humansmultivariate Cox regression; compared with metforminn = 25,635
Incidence and risk factors for osteoporosis in people with type 2 diabetes mellitus in Thailand
BMC endocrine disorders
All 15Fewer
Has thiazolidinediones been tested in people?
0 of 2 about agingYes: 1 trial and 43 observational studies in people have been published, and 2 trials are registered.
In trials
Phase 4Completed1 trial
Metabolic dysfunction-associated steatotic liver disease
Phase 2Completed1 trial
Trial sponsors
Company1 trialPhase 4112 people